Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
N/A N=20 Treatment

Imaging With a Radio Tracer to Guide VT Ablations

Ventricular Tachycardia · Arrhythmia

Bottom Line

View on ClinicalTrials.gov: NCT01250912 ↗
Enrolled (actual)
20
Serious AEs
5.0%
Results posted
Jan 2021
Primary outcome: Primary: Comparison of the Percentage of Patients With Scar in Each Segment as Determined by MIBG SPECT Versus Electroanatomic at Baseline — 2; 4; 1; 4 Participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
123I-metaiodobenzylguanidine (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
University of Maryland, Baltimore
Primary completion
Jul 2019

Outcome Measures

OutcomeResultp-value
PRIMARY
Comparison of the Percentage of Patients With Scar in Each Segment as Determined by MIBG SPECT Versus Electroanatomic at Baseline		 2; 4; 1; 4; 11; 9 —
SECONDARY
Median Segmental MIBG Uptake at Baseline		 52 —
SECONDARY
Median Segmental MIBG Uptake at 6 Months After Ablation		 48 —

Summary

Some patients are at risk for life-threatening fast heart rates. These can frequently be treated by using a catheter inside the heart to burn away the cells that create the fast heart rates. The purpose of this study is to image the nerves inside the heart of those patients. The investigators want to find out if abnormalities in the nervous system in the heart can help the physician to find the area that needs to be burnt away.

Eligibility Criteria

Inclusion Criteria

  • Patients with ventricular arrhythmias requiring VT Ablation
  • Patients must be 18 years of age or older
  • Patient must be able to sign consent form
  • Patient must be willing to come back for the 6 month visit for additional study procedures

Exclusion Criteria

  • Patient under 18 years old
  • Inability to sign consent
  • Pregnant Women
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01250912). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search